Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
BUSINESS
Twymeeg Tops GP Promotion Ranking for 3 Months Running in September: Intage
Sumitomo Pharma’s diabetes agent Twymeeg (imeglimin) held on to the number one spot in September as the most heavily detailed drug in sales reps’ face-to-face GP visits, capturing the position for the third month in a row, according to a…
To read the full story
BUSINESS
- Boehringer Ingelheim in AMD Collab with Jichi Medical University
January 31, 2023
- BMS, Kyoto University Join Hands to Deliver Innovative Drugs
January 31, 2023
- Teijin Pharma’s Osteoporosis Med Ostabalo Now Available in Japan
January 31, 2023
- AnGes to Start Japan PII for NF-κB Decoy Oligo for Lower Back Pain
January 31, 2023
- Rexulti Filed for Major Depressive Disorder in Japan: Otsuka
January 31, 2023
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The advance of cell therapy is one of the most exciting innovations in medical treatment in recent years. These drugs offer potential curative treatments for severe or previously fatal diseases. In this article, I will explain features and challenges in…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…